Ieq Capital LLC acquired a new position in shares of Phibro Animal Health Co. (NASDAQ:PAHC - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 14,358 shares of the company's stock, valued at approximately $302,000.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Phibro Animal Health by 116.6% in the third quarter. Jacobs Levy Equity Management Inc. now owns 192,255 shares of the company's stock valued at $4,330,000 after purchasing an additional 103,491 shares in the last quarter. Algert Global LLC lifted its stake in Phibro Animal Health by 521.1% in the 3rd quarter. Algert Global LLC now owns 71,335 shares of the company's stock valued at $1,606,000 after acquiring an additional 59,850 shares in the last quarter. Inspire Investing LLC acquired a new position in Phibro Animal Health during the 4th quarter worth approximately $791,000. Barclays PLC grew its stake in shares of Phibro Animal Health by 25.7% during the 3rd quarter. Barclays PLC now owns 143,337 shares of the company's stock worth $3,228,000 after acquiring an additional 29,271 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Phibro Animal Health by 5.7% during the 3rd quarter. Geode Capital Management LLC now owns 507,469 shares of the company's stock worth $11,430,000 after acquiring an additional 27,201 shares in the last quarter. 99.34% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
PAHC has been the subject of several recent research reports. StockNews.com cut shares of Phibro Animal Health from a "strong-buy" rating to a "buy" rating in a report on Thursday, February 6th. Morgan Stanley increased their price objective on shares of Phibro Animal Health from $20.00 to $25.00 and gave the stock an "equal weight" rating in a research note on Tuesday, December 17th. Finally, Barclays lifted their target price on Phibro Animal Health from $20.00 to $22.00 and gave the company an "underweight" rating in a research report on Monday, February 10th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $21.00.
Read Our Latest Analysis on Phibro Animal Health
Phibro Animal Health Stock Performance
PAHC stock traded up $1.72 during trading hours on Monday, reaching $24.46. The stock had a trading volume of 433,015 shares, compared to its average volume of 235,123. The stock has a 50-day simple moving average of $22.24 and a 200 day simple moving average of $22.34. Phibro Animal Health Co. has a fifty-two week low of $11.98 and a fifty-two week high of $26.55. The stock has a market capitalization of $990.58 million, a PE ratio of 50.95, a price-to-earnings-growth ratio of 0.45 and a beta of 0.52. The company has a debt-to-equity ratio of 2.99, a current ratio of 3.20 and a quick ratio of 1.37.
Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.54 EPS for the quarter, topping analysts' consensus estimates of $0.40 by $0.14. Phibro Animal Health had a return on equity of 25.35% and a net margin of 1.75%. Analysts predict that Phibro Animal Health Co. will post 1.95 EPS for the current fiscal year.
Phibro Animal Health Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 26th. Shareholders of record on Wednesday, March 5th will be issued a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a yield of 1.96%. The ex-dividend date is Wednesday, March 5th. Phibro Animal Health's dividend payout ratio is 100.00%.
Phibro Animal Health Profile
(
Free Report)
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.
Featured Articles
Before you consider Phibro Animal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phibro Animal Health wasn't on the list.
While Phibro Animal Health currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
